Considering that patients with HER2-positive and HER2-low-expression BC represent 2 distinct populations, we compared their PFS, and the results showed a statistically significant difference (6.6 vs 4.1 months, P = .023, Figure 2C). Here, ERBB2 is linked to breast cancer.